Amorolfine
No products yet
We're still adding products with this ingredient. Check back soon.
The full amorolfine guide
A nail is not skin, and that single fact governs everything about treating a fungal one.
There is no absorption to rely on, no living tissue to carry a drug inward — just a compressed keratin plate that a treatment has to physically penetrate and then keep penetrating for months. Amorolfine's answer is to abandon the cream format entirely and arrive as a lacquer that dries into a film and releases drug into the plate for a week at a time.
Where the evidence stands, by concern
Evidence for an ingredient is not one grade — it differs concern by concern. Each row below was researched separately against regulatory approvals, clinical guidelines, and trials our team opened and verified; the band and dots rank how central amorolfine is to treating that concern, from first-line therapy down to supportive care, at treatment-level doses and vehicles. A product's own grade weighs its actual formula.
How it's regulated in the US
FDA does not classify ingredients — it classifies products, by what they are sold to do. The same molecule can be a drug active in one product and a cosmetic ingredient in the next, and only the claim on the label decides which. What follows is a statement about that legal standing, not about whether it works — the evidence question is answered separately above.
No US standing Amorolfine is a licensed nail lacquer in the UK and across Europe and has never been approved in the US at all. American readers researching it are reading about a drug they cannot legally buy here, which is worth knowing before the shopping starts.
Approved as a drug outside the US
- nail fungus Not US-approved 5 percent w/v medicated nail lacquer
UK marketing authorization. No FDA approval and no US monograph standing.
Amorolfine 5% nail lacquer is a regulated antifungal in the UK and much of Europe — it is not FDA-approved in the United States — and it appears in the British Association of Dermatologists' onychomycosis guidelines. Manufacturer and trial data report mycological and clinical cure in roughly 45-50% of patients treated once or twice weekly for six months, assessed three months after treatment. The independent picture is more restrained: the 2020 Cochrane review of topical and device-based treatments for toenail fungus rated the evidence for topical agents generally as low-certainty, and a randomized trial of terbinafine 10% nail lacquer used amorolfine 5% as the active comparator rather than as an established benchmark. A dose-comparison found 5% superior to 2% once weekly, so the marketed strength is the studied strength — but the overall confidence in topical monotherapy for nail fungus remains modest, which is why combination with an oral agent has its own meta-analysis.
How it works
Amorolfine is a morpholine, structurally unrelated to the azoles, and it attacks fungal membrane synthesis at two points rather than one. Ergosterol — the sterol that gives a fungal membrane its structure, the way cholesterol does ours — is built through a long chain of enzymatic steps. Amorolfine blocks two of them: the delta-14 reductase and the delta-7-delta-8 isomerase. Ergosterol runs out, and an abnormal sterol called ignosterol accumulates in its place. A membrane built from the wrong sterol does not work. Permeability goes wrong, membrane-bound enzymes misbehave, and the cell's metabolism unravels — fungistatic at lower exposure, fungicidal at higher. Hitting two sequential steps rather than one is also why amorolfine has a broad spectrum across dermatophytes, yeasts and moulds. The lacquer is not packaging, it is the delivery system. Applied to a filed nail, it dries into an occlusive film that acts as a drug reservoir, driving amorolfine into the plate steadily enough that once-weekly application maintains fungicidal concentrations inside the keratin. This is why the evidence belongs specifically to the lacquer and cannot be lent to creams, oils or nail serums containing related actives — the vehicle is doing half the work.
Key benefits
- Broad spectrum across dermatophytes, yeasts and moulds via dual enzyme blockade
- Once-weekly application rather than a daily regimen
- Lacquer film acts as a reservoir, sustaining drug levels inside the nail plate
- Avoids the liver monitoring and drug interactions of oral antifungals
- Meta-analysis supports its use alongside a systemic agent for better outcomes
- Named in the British Association of Dermatologists' onychomycosis guidelines
Concentration & usage
The 5% lacquer is the only meaningful presentation — there is no lower-strength cosmetic version, and a randomized comparison found 5% outperformed 2% at once-weekly dosing. Application is once weekly to affected nails, after filing the diseased surface with the supplied file and cleaning the nail with the alcohol swab; that preparation step is part of the dose, since an unfiled nail resists penetration. Treatment runs six months for fingernails and about twelve for toenails, because the drug does not repair damaged keratin — it protects the new nail growing out behind it, and toenails simply grow slowly. Anything shorter than the trial durations is untested. Cosmetic nail polish should go on over the dried lacquer, not under it.
Who it's for & who should be cautious
Who it's for
It suits mild-to-moderate onychomycosis affecting the distal part of the nail without involvement of the matrix, and it suits people for whom oral antifungals are unattractive — those on interacting medications, with liver concerns, or simply unwilling to take a systemic drug for a nail. It is also a reasonable adjunct alongside oral terbinafine or itraconazole in more extensive disease, where a meta-analysis supports the combination outperforming the systemic agent alone. Anyone able to commit to a full year of weekly applications is a better candidate than anyone hoping for a quick result.
Who should be cautious
If the infection reaches the nail matrix, involves more than about half the plate, or affects several nails, topical monotherapy is likely to disappoint and an oral antifungal is the appropriate conversation. Nobody should start it without a confirmed diagnosis — roughly half of thickened, discoloured nails presenting as fungal turn out to be psoriasis, trauma or another nail dystrophy, and a year of lacquer will do nothing for any of them. It is not FDA-approved in the US, so American readers encountering it online are looking at an import rather than a regulated domestic product. Pregnancy and breastfeeding data are limited and use is generally avoided. People with poor circulation or diabetes affecting the feet should be managed by a clinician rather than self-treating.
Pairs with & conflicts
Pairs well with: Urea (Carbamide), Salicylic Acid (BHA)
Myths & facts
Myth: Nail fungus treatments do not work, so there is no point trying a lacquer.
Reality: The pessimism is understandable but overdrawn. Reported mycological and clinical cure with amorolfine sits around 45-50% in the manufacturer and trial data, and independent reviews rate the evidence as low-certainty rather than negative. What is true is that topical monotherapy underperforms in extensive disease and that people routinely abandon treatment months before the nail has grown out. The realistic framing is a coin-flip chance over a year, better if combined with an oral agent.
Myth: You can rub in amorolfine cream or use a nail oil with the same active for the same effect.
Reality: The lacquer vehicle is doing structural work — it dries into an occlusive film that keeps releasing drug into the keratin between weekly applications. Trial evidence generated with a lacquer does not transfer to creams, oils or brush-on 'nail serums', however similar the active on the label. A nail is not skin, and format is not a cosmetic preference here.
Myth: If the nail still looks bad after six months, the treatment has failed.
Reality: Amorolfine does not restore damaged keratin. The discoloured, thickened part of the nail stays discoloured and thickened until it grows off the end — which for a toenail takes nine to twelve months. The signal to watch is the new nail emerging at the base: clear, normal growth there means the treatment is working even while the old nail still looks awful.
Frequently asked questions
How long does amorolfine take to clear a toenail?
Around twelve months for toenails and six for fingernails, because success is limited by nail growth rate rather than by how fast the drug kills the fungus. Trials ran six to twelve months, and shorter courses are simply untested. Judge progress by the appearance of the newly grown nail at the base, not the old plate.
Do I really have to file the nail before applying it?
Yes — filing the diseased surface and cleaning with the alcohol swab is part of the dosing instructions, not an optional refinement. An intact, thickened plate resists penetration, and skipping the step meaningfully reduces how much drug reaches the infection. Use a separate file for infected nails and discard it, to avoid seeding healthy ones.
Can I wear nail polish while using amorolfine?
Cosmetic polish goes on top of the dried medicated lacquer, never underneath, and should be removed along with the lacquer before the next weekly application. Layering polish under the treatment blocks the delivery entirely. Acetone remover is fine — reapply the amorolfine after cleaning the nail.
Is amorolfine available in the United States?
No. It is authorized in the UK and much of Europe, sold under names such as Loceryl and Curanail, but it is not FDA-approved in the US. The domestic topical options there are ciclopirox, efinaconazole and tavaborole. Anything sold to a US buyer as amorolfine is an import outside the regulated supply chain.
Should I use amorolfine on its own or with tablets?
For mild distal disease in one or two nails, lacquer alone is a reasonable attempt. For more extensive involvement, a meta-analysis found amorolfine combined with a systemic antifungal produced better outcomes than the oral agent alone — the drugs reach the infection by different routes. That decision belongs with a clinician who can confirm the diagnosis first.